Xeris Biopharma Holdings, Inc. - Common Stock (XERS)
3.6200
-0.0500 (-1.36%)
Xeris Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for patients with chronic diseases and conditions
Utilizing its proprietary technology platforms, the company aims to enhance the delivery of injectable medications, creating formulations that are designed to be more convenient and effective for patients. Xeris is dedicated to addressing unmet medical needs by bringing forward products that can improve treatment experiences and outcomes for individuals with conditions such as diabetes and other specialty therapy needs.
XERS stock results show that Xeris Biopharma Holdings beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
XERS stock results show that Xeris Biopharma Holdings missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Xeris Biopharma shares are up Monday after the company announced an exclusive worldwide collaboration and license agreement with Beta Bionics. Xeris said it will work with Beta Bionics to develop and release a glucagon product that will utilize the company's XeriSol technology and Beta Bionic's pump systems.
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSELW) rose during Thursday’s session following better-than-expected quarterly results.
The Dow Jones closed lower by around 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Companies Reporting Before The Bell • Kosmos Energy (NYSEKOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.
Companies Reporting Before The Bell • Daktronics (NASDAQDAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.
